{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:10:21Z","timestamp":1792285821672,"version":"4.4.0"},"reference-count":503,"publisher":"Oxford University Press (OUP)","issue":"12","funder":[{"DOI":"10.13039\/100006292","name":"Infectious Diseases Society of America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006292","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001949","name":"American Society of Tropical Medicine and Hygiene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>It is important to realize that leishmaniasis guidelines cannot always account for individual variation among patients. They are not intended to supplant physician judgment with respect to particular patients or special clinical situations. The IDSA and ASTMH consider adherence to these guidelines to be voluntary, with the ultimate determinations regarding their application to be made by the physician in the light of each patient\u2019s individual circumstances.<\/jats:p>","DOI":"10.1093\/cid\/ciw670","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T19:05:37Z","timestamp":1475521537000},"page":"e202-e264","source":"Crossref","is-referenced-by-count":321,"title":["Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)"],"prefix":"10.1093","volume":"63","author":[{"given":"Naomi","family":"Aronson","sequence":"first","affiliation":[{"name":"\u00a0Uniformed Services University of the Health Sciences, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara L","family":"Herwaldt","sequence":"additional","affiliation":[{"name":"\u00a0Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Libman","sequence":"additional","affiliation":[{"name":"\u00a0McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pearson","sequence":"additional","affiliation":[{"name":"\u00a0University of Virginia School of Medicine, Charlottesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rogelio","family":"Lopez-Velez","sequence":"additional","affiliation":[{"name":"\u00a0Ram\u00f3n y Cajal University Hospital, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Weina","sequence":"additional","affiliation":[{"name":"\u00a0Walter Reed National Military Medical Center, Bethesda, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar M","family":"Carvalho","sequence":"additional","affiliation":[{"name":"\u00a0Gon\u00e7alo Moniz Research Center, FIOCRUZ, Salvador, Bahia, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moshe","family":"Ephros","sequence":"additional","affiliation":[{"name":"\u00a0Carmel Medical Center, Haifa, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Jeronimo","sequence":"additional","affiliation":[{"name":"\u00a0Federal University of Rio Grande do Norte, Natal, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Magill","sequence":"additional","affiliation":[{"name":"\u00a0Bill and Melinda Gates Foundation, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,12,7]]},"reference":[{"key":"2020110410511424800_CIW670C1","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2020110410511424800_CIW670C2","first-page":"Ed000055","article-title":"Cochrane reviews on neglected diseases: the case of cutaneous leishmaniasis","volume":"3","author":"Gonzalez","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410511424800_CIW670C3","first-page":"CD005067","article-title":"Interventions for Old World cutaneous leishmaniasis","volume":"4","author":"Gonzalez","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410511424800_CIW670C4","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2020110410511424800_CIW670C5","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/313924","article-title":"Cutaneous leishmaniasis following local trauma: a clinical pearl","volume":"31","author":"Wortmann","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4269\/ajtmh.1992.47.47","article-title":"Epidemiologic investigation of an outbreak of cutaneous leishmaniasis in a defined geographic focus of transmission","volume":"47","author":"Sanchez","year":"1992","journal-title":"Am J Trop Med Hyg"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C7","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1179\/000349803225002589","article-title":"Leishmania and HIV co-infection: dermatological manifestations","volume":"97","author":"Puig","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C8","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/archderm.142.10.1368","article-title":"Leishmania major cutaneous leishmaniasis in HIV-positive patients does not spread to extralesional sites","volume":"142","author":"Foulet","year":"2006","journal-title":"Arch Dermatol"},{"key":"2020110410511424800_CIW670C9","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2133.2004.06226.x","article-title":"Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana","volume":"151","author":"Couppie","year":"2004","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C10","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4269\/ajtmh.2011.11-0075","article-title":"American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon","volume":"85","author":"Guerra","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C11","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1128\/CMR.00061-07","article-title":"The relationship between leishmaniasis and AIDS: the second 10 years","volume":"21","author":"Alvar","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"2020110410511424800_CIW670C12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2133.2008.08908.x","article-title":"Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World","volume":"160","author":"Lindoso","year":"2009","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1440-0960.2007.00323.x","article-title":"Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa","volume":"48","author":"Niamba","year":"2007","journal-title":"Australas J Dermatol"},{"key":"2020110410511424800_CIW670C14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0151-9638(06)70958-9","article-title":"Cutaneous leishmania in HIV patient in Ouagadougou: clinical and therapeutic aspects [in French]","volume":"133","author":"Niamba","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"2020110410511424800_CIW670C15","first-page":"282","article-title":"Diffuse cutaneous leishmaniasis and acquired immunodeficiency syndrome in a Senegalese patient [in French]","volume":"89","author":"Ndiaye","year":"1996","journal-title":"Bull Soc Pathol Exot"},{"key":"2020110410511424800_CIW670C16","doi-asserted-by":"crossref","first-page":"555","DOI":"10.4269\/ajtmh.2009.09-0268","article-title":"Co-infection of Leishmania (Viannia) braziliensis and HIV: report of a case of mucosal leishmaniasis in Cochabamba, Bolivia","volume":"81","author":"Torrico","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1468-3083.1998.tb00739.x","article-title":"American cutaneous leishmaniasis associated with HIV infection: report of four cases","volume":"10","author":"Mattos","year":"1998","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020110410511424800_CIW670C18","first-page":"142","article-title":"Cutaneous leishmaniasis coinfection in AIDS patients: case report and literature review","volume":"1","author":"Mota Sasaki","year":"1997","journal-title":"Braz J Infect Dis"},{"key":"2020110410511424800_CIW670C19","doi-asserted-by":"crossref","first-page":"e3255","DOI":"10.1371\/journal.pntd.0003255","article-title":"Caseating granulomas in cutaneous leishmaniasis","volume":"8","author":"Aoun","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C20","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1136\/bmj.329.7470.842","article-title":"Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America","volume":"329","author":"Ahluwalia","year":"2004","journal-title":"BMJ"},{"key":"2020110410511424800_CIW670C21","doi-asserted-by":"crossref","first-page":"515","DOI":"10.4269\/ajtmh.2010.10-0081","article-title":"Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses","volume":"83","author":"Camargo","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C22","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/0035-9203(86)90243-9","article-title":"Mucosal leishmaniasis (\u201cespundia\u201d Escomel, 1911)","volume":"80","author":"Marsden","year":"1986","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C23","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.301.6753.656","article-title":"Mucocutaneous leishmaniasis","volume":"301","author":"Marsden","year":"1990","journal-title":"BMJ"},{"key":"2020110410511424800_CIW670C24","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1086\/600109","article-title":"Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species","volume":"200","author":"Figueroa","year":"2009","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S1808-8694(15)31181-2","article-title":"Mucosal leishmaniasis: epidemiological and clinical aspects","volume":"73","author":"Lessa","year":"2007","journal-title":"Braz J Otorhinolaryngol"},{"key":"2020110410511424800_CIW670C26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/infdis\/156.1.73","article-title":"Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis","volume":"156","author":"Jones","year":"1987","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1046\/j.1365-4362.2000.00969.x","article-title":"American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics","volume":"39","author":"de Oliveira-Neto","year":"2000","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1590\/S0037-86821994000200008","article-title":"Eustachian tube blockage with consequent middle ear infection in mucosal leishmaniasis","volume":"27","author":"Lessa","year":"1994","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4269\/ajtmh.2009.81.384","article-title":"The value of the otorhinolaryngologic exam in correct mucocutaneous leishmaniasis diagnosis","volume":"81","author":"Boaventura","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C30","doi-asserted-by":"crossref","first-page":"e26395","DOI":"10.1371\/journal.pone.0026395","article-title":"Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology","volume":"6","author":"Boggild","year":"2011","journal-title":"PLoS One"},{"key":"2020110410511424800_CIW670C31","first-page":"3091","article-title":"Leishmania species. Chapter 277","volume-title":"Principles and practice of infectious diseases","author":"Magill","year":"2015","edition":"8th ed"},{"key":"2020110410511424800_CIW670C32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/B978-1-4160-4390-4.00099-0","article-title":"Leishmaniasis. Chapter 99","volume-title":"Hunter\u2019s Tropical Medicine and Emerging Infectious Diseases","author":"Magill","year":"2013","edition":"9th ed"},{"key":"2020110410511424800_CIW670C33","first-page":"1095","article-title":"Leishmaniasis","volume-title":"principles, pathogens, and practice","author":"Jeronimo","year":"2006","edition":"2nd ed"},{"key":"2020110410511424800_CIW670C34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QCO.0b013e32835c2198","article-title":"Clinical aspects of visceral leishmaniasis in HIV infection","volume":"26","author":"Jarvis","year":"2013","journal-title":"Curr Opin Infect Dis"},{"key":"2020110410511424800_CIW670C35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1590\/0037-8682-0180-2013","article-title":"HIV\/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil","volume":"47","author":"Albuquerque","year":"2014","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1365-3156.2010.02550.x","article-title":"Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia","volume":"15","author":"Hurissa","year":"2010","journal-title":"Trop Med Int Health"},{"key":"2020110410511424800_CIW670C37","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0035-9203(01)90110-5","article-title":"Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome","volume":"95","author":"Ritmeijer","year":"2001","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00005792-200101000-00006","article-title":"Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study","volume":"80","author":"Pintado","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"2020110410511424800_CIW670C39","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10096-005-1342-6","article-title":"Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region","volume":"24","author":"Pasquau","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410511424800_CIW670C40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.4269\/ajtmh.1998.58.436","article-title":"Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunodeficiency virus and Leishmania in an area of Madrid, Spain","volume":"58","author":"Lopez-Velez","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C41","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1086\/318135","article-title":"HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania","volume":"31","author":"Rosenthal","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C42","article-title":"Control of the leishmaniases. World Health Organization technical report series.","author":"World Health Organization","year":"2010"},{"key":"2020110410511424800_CIW670C43","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1046\/j.1365-4362.2002.01610.x","article-title":"Presence of Leishmania organisms in specific and non-specific skin lesions in HIV-infected individuals with visceral leishmaniasis","volume":"41","author":"Bosch","year":"2002","journal-title":"Int J Dermatol"},{"issue":"5 pt 2","key":"2020110410511424800_CIW670C44","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S0190-9622(99)70342-7","article-title":"Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection","volume":"41","author":"Colebunders","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/archderm.142.6.787","article-title":"Cutaneous manifestations of visceral leishmaniasis resistant to liposomal amphotericin B in an HIV-positive patient","volume":"142","author":"Alsina-Gibert","year":"2006","journal-title":"Arch Dermatol"},{"key":"2020110410511424800_CIW670C46","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1046\/j.1365-2133.1998.02326.x","article-title":"Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus","volume":"139","author":"Ara","year":"1998","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00000372-199504000-00006","article-title":"Atypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome","volume":"17","author":"Perrin","year":"1995","journal-title":"Am J Dermatopathol"},{"key":"2020110410511424800_CIW670C48","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1046\/j.1365-2133.2000.03909.x","article-title":"Kaposi\u2019s sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis","volume":"143","author":"Gonzalez-Beato","year":"2000","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C49","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/ijd.12139","article-title":"Post-kala-azar dermal leishmaniasis in HIV-infected patients with AIDS: a report of two cases diagnosed in the USA","volume":"52","author":"Farooq","year":"2013","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C50","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1128\/JCM.44.3.1178-1180.2006","article-title":"Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient","volume":"44","author":"Stark","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C51","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1590\/S1413-86702002000600008","article-title":"Post-kala-azar dermal leishmaniasis associated with AIDS","volume":"6","author":"Bittencourt","year":"2002","journal-title":"Braz J Infect Dis"},{"key":"2020110410511424800_CIW670C52","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jinf.2005.09.015","article-title":"Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe","volume":"53","author":"Rihl","year":"2006","journal-title":"J Infect"},{"key":"2020110410511424800_CIW670C53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0151-9638(06)70841-9","article-title":"Leishmania infantum\/HIV co-infection: cutaneous lesions following treatment of visceral leishmaniasis [in French]","volume":"133","author":"Catorze","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"2020110410511424800_CIW670C54","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.1016\/j.ijid.2009.01.022","article-title":"Atypical disseminated leishmaniasis similar to post-kala-azar dermal leishmaniasis in a Brazilian AIDS patient infected with Leishmania (Leishmania) infantum chagasi: a case report","volume":"13","author":"Carnauba","year":"2009","journal-title":"Int J Infect Dis"},{"key":"2020110410511424800_CIW670C55","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/S0140-6736(98)10178-2","article-title":"Leishmaniasis","volume":"354","author":"Herwaldt","year":"1999","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C56","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1128\/JCM.02457-10","article-title":"Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis","volume":"49","author":"Boggild","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C57","doi-asserted-by":"crossref","first-page":"345","DOI":"10.4269\/ajtmh.2010.09-0414","article-title":"Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis","volume":"83","author":"Boggild","year":"2010","journal-title":"Am J Trop Med Hyg"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C58","first-page":"S169","article-title":"The method used to sample ulcers influences the diagnosis of cutaneous leishmaniasis","volume":"96","author":"Robinson","year":"2002","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C59","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1128\/JCM.38.10.3768-3773.2000","article-title":"Diagnosis of cutaneous leishmaniasis in Colombia: the sampling site within lesions influences the sensitivity of parasitologic diagnosis","volume":"38","author":"Ramirez","year":"2000","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C60","doi-asserted-by":"crossref","first-page":"36","DOI":"10.4269\/ajtmh.1990.42.36","article-title":"Cutaneous leishmaniasis in Guatemala: comparison of diagnostic methods","volume":"42","author":"Navin","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4269\/ajtmh.1987.36.489","article-title":"Diagnosis of cutaneous and mucocutaneous leishmaniasis in Colombia: a comparison of seven methods","volume":"36","author":"Weigle","year":"1987","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C62","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1128\/JCM.02029-06","article-title":"Molecular diagnosis of leishmaniasis: current status and future applications","volume":"45","author":"Reithinger","year":"2007","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C63","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4269\/ajtmh.1923.s1-3.117","article-title":"The pathology of leishmaniosis of the nose","volume":"3","author":"Klotz","year":"1923","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C64","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1128\/JCM.00208-13","article-title":"Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters","volume":"51","author":"Jara","year":"2013","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C65","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.diagmicrobio.2014.05.002","article-title":"Mucocutaneous leishmaniasis: accuracy and molecular validation of noninvasive procedures in a L. (V.) braziliensis-endemic area","volume":"79","author":"Gomes","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020110410511424800_CIW670C66","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.pt.2014.05.006","article-title":"The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis","volume":"30","author":"Hartley","year":"2014","journal-title":"Trends Parasitol"},{"key":"2020110410511424800_CIW670C67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4269\/ajtmh.1998.59.49","article-title":"Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics","volume":"59","author":"Osorio","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C68","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4269\/ajtmh.2006.75.267","article-title":"Concomitant early mucosal and cutaneous leishmaniasis in Brazil","volume":"75","author":"Boaventura","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C69","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1086\/345772","article-title":"Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil","volume":"186","author":"Turetz","year":"2002","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C70","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.trstmh.2012.03.007","article-title":"A proposed new clinical staging system for patients with mucosal leishmaniasis","volume":"106","author":"Lessa","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C71","doi-asserted-by":"crossref","first-page":"858","DOI":"10.4269\/ajtmh.2006.75.858","article-title":"Reference values for Leishmania infantum parasitemia in different clinical presentations: quantitative polymerase chain reaction for therapeutic monitoring and patient follow-up","volume":"75","author":"Mary","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C72","first-page":"951","article-title":"Laboratory diagnosis of visceral leishmaniasis","volume":"9","author":"Sundar","year":"2002","journal-title":"Clin Diagn Lab Immunol"},{"key":"2020110410511424800_CIW670C73","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4269\/ajtmh.2005.72.811","article-title":"Sensitivity of bone marrow aspirates in the diagnosis of visceral leishmaniasis","volume":"72","author":"da Silva","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C74","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/S0035-9203(97)90516-2","article-title":"A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis","volume":"91","author":"Thakur","year":"1997","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C75","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1128\/JCM.05067-11","article-title":"Peripheral blood buffy coat smear: a promising tool for diagnosis of visceral leishmaniasis","volume":"50","author":"Salam","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C76","article-title":"Visceral leishmaniasis rapid diagnostic test performance. Diagnostic evaluation series No. 4","author":"World Health Organization","year":"2011"},{"key":"2020110410511424800_CIW670C77","first-page":"CD009135","article-title":"Rapid tests for the diagnosis of visceral leishmaniasis in patients with suspected disease","volume":"6","author":"Boelaert","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410511424800_CIW670C78","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.idc.2012.03.005","article-title":"Visceral leishmaniasis","volume":"26","author":"van Griensven","year":"2012","journal-title":"Infect Dis Clin North Am"},{"key":"2020110410511424800_CIW670C79","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1128\/JCM.00130-11","article-title":"Noninvasive molecular diagnosis of human visceral leishmaniasis","volume":"49","author":"Vaish","year":"2011","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C80","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1086\/425747","article-title":"Old World leishmaniasis: an emerging infection among deployed US military and civilian workers","volume":"39","author":"Weina","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C81","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1586\/eri.10.19","article-title":"Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis","volume":"8","author":"Goto","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020110410511424800_CIW670C82","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/1469-0691.12387","article-title":"Identification of Leishmania at the species level with matrix-assisted laser desorption ionization time-of-flight mass spectrometry","volume":"20","author":"Cassagne","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410511424800_CIW670C83","doi-asserted-by":"crossref","first-page":"e2841","DOI":"10.1371\/journal.pntd.0002841","article-title":"Easy identification of leishmania species by mass spectrometry","volume":"8","author":"Mouri","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C84","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1128\/CMR.00104-14","article-title":"Species typing in dermal leishmaniasis","volume":"28","author":"Van der Auwera","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"2020110410511424800_CIW670C85","doi-asserted-by":"crossref","first-page":"e2832","DOI":"10.1371\/journal.pntd.0002832","article-title":"Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide","volume":"8","author":"Hodiamont","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C86","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1473-3099(08)70043-4","article-title":"Leishmaniasis among organ transplant recipients","volume":"8","author":"Antinori","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C87","doi-asserted-by":"crossref","first-page":"e1153","DOI":"10.1371\/journal.pntd.0001153","article-title":"Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review","volume":"5","author":"Cota","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C88","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1586\/14737159.3.5.657","article-title":"Molecular diagnosis of leishmaniasis","volume":"3","author":"Tavares","year":"2003","journal-title":"Expert Rev Mol Diagn"},{"key":"2020110410511424800_CIW670C89","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1128\/JCM.00372-14","article-title":"Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy","volume":"52","author":"de Ruiter","year":"2014","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C90","doi-asserted-by":"crossref","first-page":"5249","DOI":"10.1128\/JCM.42.11.5249-5255.2004","article-title":"Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity","volume":"42","author":"Mary","year":"2004","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C91","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4269\/ajtmh.2001.65.583","article-title":"Rapid diagnosis of leishmaniasis by fluorogenic polymerase chain reaction","volume":"65","author":"Wortmann","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s10096-010-1071-3","article-title":"Universal PCR assays for the differential detection of all Old World Leishmania species","volume":"30","author":"Odiwuor","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410511424800_CIW670C93","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4269\/ajtmh.2007.76.906","article-title":"Diagnosis of cutaneous leishmaniasis in Guatemala using a real-time polymerase chain reaction assay and the Smartcycler","volume":"76","author":"Wortmann","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C94","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.pt.2010.06.013","article-title":"Is it time to revise the nomenclature of Leishmania?","volume":"26","author":"Schonian","year":"2010","journal-title":"Trends Parasitol"},{"key":"2020110410511424800_CIW670C95","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1128\/CVI.00174-08","article-title":"Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis","volume":"15","author":"Welch","year":"2008","journal-title":"Clin Vaccine Immunol"},{"key":"2020110410511424800_CIW670C96","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1073\/pnas.90.2.775","article-title":"Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis","volume":"90","author":"Burns","year":"1993","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2020110410511424800_CIW670C97","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1136\/bmj.38917.503056.7C","article-title":"A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis","volume":"333","author":"Chappuis","year":"2006","journal-title":"BMJ"},{"key":"2020110410511424800_CIW670C98","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1086\/342057","article-title":"Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit","volume":"35","author":"Sundar","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C99","doi-asserted-by":"crossref","first-page":"344","DOI":"10.4269\/ajtmh.2002.67.344","article-title":"The sensitivity and specificity of Leishmania chagasi recombinant K39 antigen in the diagnosis of American visceral leishmaniasis and in differentiating active from subclinical infection","volume":"67","author":"Braz","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C100","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1128\/JCM.02620-15","article-title":"Accurate serodetection of asymptomatic Leishmania donovani infection by use of defined antigens","volume":"54","author":"Vallur","year":"2016","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C101","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4269\/ajtmh.13-0759","article-title":"Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients","volume":"91","author":"Bezuneh","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C102","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000822","article-title":"Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis","volume":"4","author":"Pattabhi","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C103","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4269\/ajtmh.2006.74.76","article-title":"Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis","volume":"74","author":"Ritmeijer","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C104","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1128\/CVI.00473-10","article-title":"Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India","volume":"18","author":"Gidwani","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"2020110410511424800_CIW670C105","doi-asserted-by":"crossref","first-page":"76","DOI":"10.4269\/ajtmh.2008.79.76","article-title":"Evaluation of direct agglutination test, rk39 Test, and ELISA for the diagnosis of visceral leishmaniasis","volume":"79","author":"Mandal","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C106","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3109\/10408419509113537","article-title":"Serodiagnosis of leishmaniasis","volume":"21","author":"Kar","year":"1995","journal-title":"Crit Rev Microbiol"},{"key":"2020110410511424800_CIW670C107","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4269\/ajtmh.81.1.27","article-title":"Comparative study of serologic tests for the diagnosis of asymptomatic visceral leishmaniasis in an endemic area","volume":"81","author":"Romero","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C108","doi-asserted-by":"crossref","first-page":"e1665","DOI":"10.1371\/journal.pntd.0001665","article-title":"The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis","volume":"6","author":"Cota","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C109","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4269\/ajtmh.2009.80.929","article-title":"Field evaluation of rK39 test and direct agglutination test for diagnosis of visceral leishmaniasis in a population with high prevalence of human immunodeficiency virus in Ethiopia","volume":"80","author":"ter Horst","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C110","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.trstmh.2011.01.006","article-title":"The emergence of concurrent HIV-1\/AIDS and visceral leishmaniasis in northeast Brazil","volume":"105","author":"Nascimento","year":"2011","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C111","doi-asserted-by":"crossref","first-page":"843","DOI":"10.4269\/ajtmh.2008.79.843","article-title":"Positive rK39 serologic assay results in US servicemen with cutaneous leishmaniasis","volume":"79","author":"Hartzell","year":"2008","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C112","doi-asserted-by":"crossref","DOI":"10.1590\/S0074-02762013000300006","article-title":"Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil","volume":"108","author":"Molinet","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C113","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1590\/S0036-46652005000400003","article-title":"The histopathology of cutaneous leishmaniasis due to Leishmania (Leishmania) mexicana in the Yucatan peninsula, Mexico","volume":"47","author":"Andrade-Narvaez","year":"2005","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2020110410511424800_CIW670C114","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4269\/ajtmh.1991.45.281","article-title":"Correlation between histopathology, immune response, clinical presentation, and evolution in Leishmania braziliensis infection","volume":"45","author":"Gutierrez","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C115","volume-title":"Clinical parasitology","author":"Craig","year":"1943","edition":"3rd ed"},{"key":"2020110410511424800_CIW670C116","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S1473-3099(07)70209-8","article-title":"Cutaneous leishmaniasis","volume":"7","author":"Reithinger","year":"2007","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C117","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0738-081X(96)00036-3","article-title":"Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous leishmaniasis","volume":"14","author":"Weigle","year":"1996","journal-title":"Clin Dermatol"},{"key":"2020110410511424800_CIW670C118","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/S0140-6736(05)67629-5","article-title":"Advances in leishmaniasis","volume":"366","author":"Murray","year":"2005","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C119","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.inhe.2012.06.004","article-title":"Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis","volume":"4","author":"Blum","year":"2012","journal-title":"Int Health"},{"key":"2020110410511424800_CIW670C120","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/0002-9343(75)90405-2","article-title":"Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B","volume":"59","author":"Singer","year":"1975","journal-title":"Am J Med"},{"key":"2020110410511424800_CIW670C121","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/00313029800169715","article-title":"New World cutaneous leishmaniasis imported into Australia","volume":"30","author":"Maguire","year":"1998","journal-title":"Pathology"},{"key":"2020110410511424800_CIW670C122","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1017\/S0022215100139106","article-title":"Leishmania braziliensis presenting as a granulomatous lesion of the nasal septum mucosa","volume":"111","author":"Lohuis","year":"1997","journal-title":"J Laryngol Otol"},{"key":"2020110410511424800_CIW670C123","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2230.1996.tb00097.x","article-title":"Imported mucocutaneous leishmaniasis","volume":"21","author":"Rosbotham","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"2020110410511424800_CIW670C124","first-page":"1025","article-title":"Erroneous tracks in the diagnosis of cutaneous and mucocutaneous leishmaniasis [in German]","volume":"83","author":"Blum","year":"1994","journal-title":"Schweiz Rundsch Med Prax"},{"key":"2020110410511424800_CIW670C125","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/377045","article-title":"Imported mucosal leishmaniasis in a traveler","volume":"37","author":"Scope","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C126","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1093\/qjmed\/hch127","article-title":"New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers","volume":"97","author":"Lawn","year":"2004","journal-title":"QJM"},{"key":"2020110410511424800_CIW670C127","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1684\/ejd.2013.1934","article-title":"Clinical complexity of Leishmania (Viannia) braziliensis infections amongst travelers","volume":"23","author":"Eichner","year":"2013","journal-title":"Eur J Dermatol"},{"key":"2020110410511424800_CIW670C128","doi-asserted-by":"crossref","first-page":"20544","DOI":"10.2807\/1560-7917.ES2013.18.30.20544","article-title":"Imported leishmaniasis in the Netherlands from 2005 to 2012: epidemiology, diagnostic techniques and sequence-based species typing from 195 patients","volume":"18","author":"Bart","year":"2013","journal-title":"Euro Surveill"},{"key":"2020110410511424800_CIW670C129","doi-asserted-by":"crossref","first-page":"20534","DOI":"10.2807\/1560-7917.ES2013.18.29.20534","article-title":"Surveillance of leishmaniases in France, 1999 to 2012","volume":"18","author":"Lachaud","year":"2013","journal-title":"Euro Surveill"},{"key":"2020110410511424800_CIW670C130","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1708-8305.2011.00572.x","article-title":"Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment","volume":"19","author":"Neumayr","year":"2012","journal-title":"J Travel Med"},{"key":"2020110410511424800_CIW670C131","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0035-9203(03)90084-8","article-title":"New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate","volume":"97","author":"Lawn","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C132","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S1473-3099(06)70492-3","article-title":"New world cutaneous leishmaniasis in travellers","volume":"6","author":"Schwartz","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C133","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1590\/S0074-02762001000200005","article-title":"Clinical picture of cutaneous leishmaniases due to Leishmania (Leishmania) mexicana in the Yucatan Peninsula, Mexico","volume":"96","author":"Andrade-Narvaez","year":"2001","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C134","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4269\/ajtmh.1989.41.280","article-title":"Diffuse cutaneous leishmaniasis in Mexico","volume":"41","author":"Velasco","year":"1989","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C135","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00436-011-2356-x","article-title":"Mucosal Leishmania infantum infection","volume":"109","author":"Richter","year":"2011","journal-title":"Parasitol Res"},{"key":"2020110410511424800_CIW670C136","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0035-9203(94)90294-1","article-title":"Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia, caused by an enzymatic variant of Leishmania panamensis","volume":"88","author":"Velez","year":"1994","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C137","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-4362.1996.tb03655.x","article-title":"Disseminated American cutaneous leishmaniasis","volume":"35","author":"Bonfante-Garrido","year":"1996","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C138","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1590\/S0074-02762004000300001","article-title":"Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review","volume":"99","author":"Silveira","year":"2004","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C139","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1111\/j.1365-2133.2007.07872.x","article-title":"Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses","volume":"156","author":"Zerpa","year":"2007","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C140","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14712598.2014.945415","article-title":"Therapeutic vaccines for leishmaniasis","volume":"14","author":"Khamesipour","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"2020110410511424800_CIW670C141","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0140-6736(90)91945-7","article-title":"Recurrent lesions in human Leishmania braziliensis infection\u2014reactivation or reinfection?","volume":"336","author":"Saravia","year":"1990","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C142","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0035-9203(90)90321-5","article-title":"Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime","volume":"84","author":"Netto","year":"1990","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C143","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1086\/382135","article-title":"Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?","volume":"189","author":"Mendonca","year":"2004","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C144","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/000348941212101102","article-title":"Morbidity and patient perception of flexible laryngoscopy","volume":"121","author":"Paul","year":"2012","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"2020110410511424800_CIW670C145","first-page":"106","article-title":"Epidemiological, clinical and biological features of mucocutaneous leishmaniasis in Bolivia after a 221 patient sample [in French]","volume":"86","author":"Dimier-David","year":"1993","journal-title":"Bull Soc Pathol Exot"},{"key":"2020110410511424800_CIW670C146","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1590\/S0102-311X2000000400013","article-title":"The epidemiology and control of leishmaniasis in Andean countries","volume":"16","author":"Davies","year":"2000","journal-title":"Cad Saude Publica"},{"key":"2020110410511424800_CIW670C147","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-4362.1997.00188.x","article-title":"Intralesional therapy of American cutaneous leishmaniasis with pentavalent antimony in Rio de Janeiro, Brazil\u2014an area of Leishmania (V.) braziliensis transmission","volume":"36","author":"Oliveira-Neto","year":"1997","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C148","doi-asserted-by":"crossref","first-page":"651","DOI":"10.4269\/ajtmh.1997.57.651","article-title":"A low-dose antimony treatment in 159 patients with American cutaneous leishmaniasis: extensive follow-up studies (up to 10 years)","volume":"57","author":"Oliveira-Neto","year":"1997","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C149","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.medmal.2007.03.012","article-title":"Mucocutaneous leishmaniasis in Brazilian Amazonia [in French]","volume":"37","author":"Camuset","year":"2007","journal-title":"Med Mal Infect"},{"key":"2020110410511424800_CIW670C150","doi-asserted-by":"crossref","first-page":"232","DOI":"10.7326\/0003-4819-126-3-199702010-00010","article-title":"Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial","volume":"126","author":"Velez","year":"1997","journal-title":"Ann Intern Med"},{"key":"2020110410511424800_CIW670C151","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1046\/j.1365-4362.1997.00308.x","article-title":"Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis","volume":"36","author":"D\u2019Oliveira Junior","year":"1997","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C152","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/infdis\/jiv355","article-title":"Presence of Leishmania RNA virus 1 in Leishmania guyanensis increases the risk of first-line treatment failure and symptomatic relapse","volume":"213","author":"Bourreau","year":"2016","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C153","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/infdis\/jiv354","article-title":"Association of the endobiont double-stranded RNA Virus LRV1 with treatment failure for human leishmaniasis caused by Leishmania braziliensis in Peru and Bolivia","volume":"213","author":"Adaui","year":"2016","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C154","doi-asserted-by":"crossref","first-page":"E69","DOI":"10.1086\/340526","article-title":"Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer","volume":"34","author":"Machado","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C155","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1086\/524042","article-title":"Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru","volume":"46","author":"Llanos-Cuentas","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C156","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jaad.2012.06.014","article-title":"Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers","volume":"68","author":"Solomon","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C157","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/383321","article-title":"Miltefosine for new world cutaneous leishmaniasis","volume":"38","author":"Soto","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C158","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1128\/AAC.00014-08","article-title":"Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients","volume":"52","author":"Dorlo","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410511424800_CIW670C159","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1468-3083.2010.03908.x","article-title":"Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica","volume":"25","author":"Solomon","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020110410511424800_CIW670C160","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4269\/ajtmh.2010.10-0171","article-title":"Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis","volume":"83","author":"Wortmann","year":"2010","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C161","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1590\/S0365-05962011000600005","article-title":"A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis","volume":"86","author":"Neves","year":"2011","journal-title":"An Bras Dermatol"},{"key":"2020110410511424800_CIW670C162","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1590\/S0037-86821996000500007","article-title":"Comparative study of meglumine antimoniate, pentamidine isethionate and aminosidine sulfate in the treatment of primary skin lesions caused by Leishmania (Viannia) braziliensis [in Portuguese]","volume":"29","author":"Correia","year":"1996","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C163","doi-asserted-by":"crossref","first-page":"133","DOI":"10.4269\/ajtmh.2005.72.133","article-title":"Comparison of meglumine antimoniate and pentamidine for Peruvian cutaneous leishmaniasis","volume":"72","author":"Andersen","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C164","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-4632.2009.03883.x","article-title":"Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname","volume":"48","author":"van der Meide","year":"2009","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4269\/ajtmh.1994.50.107","article-title":"Successful treatment of Colombian cutaneous leishmaniasis with four injections of pentamidine","volume":"50","author":"Soto","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C166","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/clind\/16.3.417","article-title":"Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia","volume":"16","author":"Soto-Mancipe","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C167","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1093\/infdis\/165.3.528","article-title":"Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala","volume":"165","author":"Navin","year":"1992","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C168","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9343(90)90292-L","article-title":"Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis","volume":"89","author":"Saenz","year":"1990","journal-title":"Am J Med"},{"key":"2020110410511424800_CIW670C169","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1056\/NEJMoa011882","article-title":"Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major","volume":"346","author":"Alrajhi","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C170","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4269\/ajtmh.2007.76.48","article-title":"Healing of Old World cutaneous leishmaniasis in travelers treated with fluconazole: drug effect or spontaneous evolution?","volume":"76","author":"Morizot","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C171","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jaad.2010.04.014","article-title":"Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial","volume":"64","author":"Emad","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C172","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/cid\/cir496","article-title":"High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis","volume":"53","author":"Sousa","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C173","doi-asserted-by":"crossref","first-page":"300","DOI":"10.4269\/ajtmh.1983.32.300","article-title":"Thermosensitivity patterns of Old vs. New World cutaneous strains of Leishmania growing within mouse peritoneal macrophages in vitro","volume":"32","author":"Sacks","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C174","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1086\/428736","article-title":"Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial","volume":"40","author":"Reithinger","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C175","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7205\/MILMED-D-11-00161","article-title":"Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial","volume":"177","author":"Safi","year":"2012","journal-title":"Mil Med"},{"key":"2020110410511424800_CIW670C176","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1371\/journal.pntd.0000628","article-title":"A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection","volume":"4","author":"Aronson","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C177","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2230.2007.02405.x","article-title":"Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate","volume":"32","author":"Sadeghian","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"2020110410511424800_CIW670C178","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4269\/ajtmh.1990.42.43","article-title":"Placebo-controlled clinical trial of meglumine antimonate (glucantime) vs. localized controlled heat in the treatment of cutaneous leishmaniasis in Guatemala","volume":"42","author":"Navin","year":"1990","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C179","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1745-6215-13-58","article-title":"Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis","volume":"13","author":"Lopez","year":"2012","journal-title":"Trials"},{"key":"2020110410511424800_CIW670C180","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1046\/j.1365-4362.1997.00045.x","article-title":"A 2-year study of liquid nitrogen therapy in cutaneous leishmaniasis","volume":"36","author":"al-Majali","year":"1997","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C181","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1365-4632.2006.02822.x","article-title":"Comparison of intralesional meglumine antimoniate, cryotherapy and their combination in the treatment of cutaneous leishmaniasis","volume":"45","author":"Salmanpour","year":"2006","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C182","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.trstmh.2012.02.006","article-title":"Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia","volume":"106","author":"Negera","year":"2012","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C183","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/09546631003762654","article-title":"Liquid nitrogen cryotherapy on Leishmania donovani cutaneous leishmaniasis","volume":"22","author":"Ranawaka","year":"2011","journal-title":"J Dermatolog Treat"},{"key":"2020110410511424800_CIW670C184","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/j.1365-2133.1988.tb02605.x","article-title":"Cryosurgery in Old World cutaneous leishmaniasis","volume":"118","author":"Al-Gindan","year":"1988","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1046\/j.0011-9059.2001.01396.x","article-title":"Cutaneous leishmaniasis in Sanliurfa: epidemiologic and clinical features of the last four years (1997\u20132000)","volume":"41","author":"Gurel","year":"2002","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C186","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2133.1999.02673.x","article-title":"Cutaneous leishmaniasis: evaluation of 3,074 cases in the Cukurova region of Turkey","volume":"140","author":"Uzun","year":"1999","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C187","doi-asserted-by":"crossref","first-page":"770","DOI":"10.4269\/ajtmh.14-0787","article-title":"Lymphatic dissemination in cutaneous leishmaniasis following local treatment","volume":"93","author":"Thomaidou","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C188","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2230.2006.02182.x","article-title":"Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial","volume":"31","author":"Asilian","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"2020110410511424800_CIW670C189","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1111\/bjd.13490","article-title":"Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: proof of concept for a novel self-administered therapeutic modality","volume":"172","author":"Enk","year":"2015","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C190","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1468-3083.2010.03781.x","article-title":"Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate","volume":"25","author":"Meymandi","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020110410511424800_CIW670C191","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/jtm.12089","article-title":"LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014","volume":"21","author":"Blum","year":"2014","journal-title":"J Travel Med"},{"key":"2020110410511424800_CIW670C192","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3201\/eid1104.040945","article-title":"Social impact of leishmaniasis, Afghanistan","volume":"11","author":"Reithinger","year":"2005","journal-title":"Emerg Infect Dis"},{"key":"2020110410511424800_CIW670C193","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3109\/09546630903287445","article-title":"Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani","volume":"21","author":"Ranawaka","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"2020110410511424800_CIW670C194","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1080\/00034983.1997.11813217","article-title":"Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration","volume":"91","author":"Alkhawajah","year":"1997","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C195","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/0035-9203(91)90026-U","article-title":"A randomized trial comparing a pentavalent antimonial drug and recombinant interferon-gamma in the local treatment of cutaneous leishmaniasis","volume":"85","author":"Harms","year":"1991","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C196","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/cit049","article-title":"Intralesional antimony for single lesions of Bolivian cutaneous leishmaniasis","volume":"56","author":"Soto","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C197","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/j.1365-4632.2004.02002.x","article-title":"Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis","volume":"43","author":"Asilian","year":"2004","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C198","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/1523-1747.ep12696697","article-title":"Topical treatment of cutaneous leishmaniasis","volume":"87","author":"El-On","year":"1986","journal-title":"J Invest Dermatol"},{"key":"2020110410511424800_CIW670C199","doi-asserted-by":"crossref","first-page":"147","DOI":"10.4269\/ajtmh.2002.66.147","article-title":"Treatment of cutaneous leishmaniasis with a topical antileishmanial drug (WR279396): phase 2 pilot study","volume":"66","author":"Soto","year":"2002","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C200","doi-asserted-by":"crossref","first-page":"557","DOI":"10.4269\/ajtmh.12-0736","article-title":"Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama","volume":"89","author":"Sosa","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C201","doi-asserted-by":"crossref","first-page":"e381","DOI":"10.1371\/journal.pntd.0000381","article-title":"Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials","volume":"3","author":"Kim","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C202","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jaad.2005.07.026","article-title":"Leishmania tropica in northern Israel: a clinical overview of an emerging focus","volume":"53","author":"Shani-Adir","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C203","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1371\/journal.pntd.0000432","article-title":"WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study","volume":"3","author":"Ben Salah","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C204","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1056\/NEJMoa1202657","article-title":"Topical paromomycin with or without gentamicin for cutaneous leishmaniasis","volume":"368","author":"Ben Salah","year":"2013","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C205","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4269\/ajtmh.1998.58.824","article-title":"Cutaneous scars in American tegumentary leishmaniasis patients: a site of Leishmania (Viannia) braziliensis persistence and viability eleven years after antimonial therapy and clinical cure","volume":"58","author":"Schubach","year":"1998","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C206","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4269\/ajtmh.1985.34.856","article-title":"American cutaneous leishmaniasis: a comparison of three sodium stibogluconate treatment schedules","volume":"34","author":"Oster","year":"1985","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C207","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/infdis\/165.3.518","article-title":"The natural history of cutaneous leishmaniasis in Guatemala","volume":"165","author":"Herwaldt","year":"1992","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C208","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-4632.2007.03154.x","article-title":"Clinical manifestations and classification of Old World cutaneous leishmaniasis","volume":"46","author":"Akilov","year":"2007","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C209","doi-asserted-by":"crossref","first-page":"e2130","DOI":"10.1371\/journal.pntd.0002130","article-title":"Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis","volume":"7","author":"Olliaro","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C210","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1378\/chest.99.2.416","article-title":"Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test)","volume":"99","author":"Bouros","year":"1991","journal-title":"Chest"},{"key":"2020110410511424800_CIW670C211","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1086\/655134","article-title":"Designing and reporting clinical trials on treatments for cutaneous leishmaniasis","volume":"51","author":"Gonzalez","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C212","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4103\/0019-5154.77549","article-title":"Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection","volume":"56","author":"Sadeghian","year":"2011","journal-title":"Indian J Dermatol"},{"key":"2020110410511424800_CIW670C213","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/1469-0691.12556","article-title":"Leishmaniasis in immunosuppressed individuals","volume":"20","author":"van Griensven","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"2020110410511424800_CIW670C214","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/j.1468-3083.2009.03238.x","article-title":"Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil","volume":"23","author":"Amato","year":"2009","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020110410511424800_CIW670C215","first-page":"118","article-title":"Recidivant laryngeal leishmaniasis: an unusual case in an immunocompetent patient treated with corticosteroids [in Spanish]","volume":"42","author":"Casero","year":"2010","journal-title":"Rev Argent Microbiol"},{"key":"2020110410511424800_CIW670C216","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1365-4632.2006.03096.x","article-title":"Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids\u2014first report","volume":"46","author":"Tuon","year":"2007","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C217","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1086\/322643","article-title":"Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment","volume":"33","author":"Marovich","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C218","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0190-9622(08)81764-1","article-title":"Cutaneous leishmaniasis: an unusual case with atypical recurrence","volume":"28","author":"Kanj","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C219","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.3201\/eid1309.061446","article-title":"Recurrent American cutaneous leishmaniasis","volume":"13","author":"Gangneux","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"2020110410511424800_CIW670C220","doi-asserted-by":"crossref","first-page":"52","DOI":"10.4269\/ajtmh.2009.81.52","article-title":"Relapsing cutaneous leishmaniasis in a patient with ankylosing spondylitis treated with infliximab","volume":"81","author":"Mueller","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C221","doi-asserted-by":"crossref","first-page":"e1656","DOI":"10.1371\/journal.pntd.0001656","article-title":"Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions","volume":"6","author":"Valencia","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C222","doi-asserted-by":"crossref","first-page":"574","DOI":"10.4269\/ajtmh.2009.80.574","article-title":"Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil","volume":"80","author":"Unger","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C223","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1590\/S0037-86822006000200001","article-title":"Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate [in Portuguese]","volume":"39","author":"Rodrigues","year":"2006","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C224","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jiph.2012.11.003","article-title":"Efficacy of glucantime for treatment of cutaneous leishmaniasis in central Iran","volume":"6","author":"Mohammadzadeh","year":"2013","journal-title":"J Infect Public Health"},{"key":"2020110410511424800_CIW670C225","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.actatropica.2013.02.002","article-title":"Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil","volume":"126","author":"Torres","year":"2013","journal-title":"Acta Trop"},{"key":"2020110410511424800_CIW670C226","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00436-011-2555-5","article-title":"Leishmania antimony resistance: what we know what we can learn from the field","volume":"109","author":"Ait-Oudhia","year":"2011","journal-title":"Parasitol Res"},{"key":"2020110410511424800_CIW670C227","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1086\/503371","article-title":"Resistance to antimony and treatment failure in human Leishmania (Viannia) infection","volume":"193","author":"Rojas","year":"2006","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C228","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1086\/518172","article-title":"Role of imiquimod and parenteral meglumine antimoniate in the initial treatment of cutaneous leishmaniasis","volume":"44","author":"Arevalo","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C229","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/511643","article-title":"Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis","volume":"44","author":"Machado","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C230","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4269\/ajtmh.2001.65.87","article-title":"Successful treatment of refractory mucosal leishmaniasis with pentoxifylline plus antimony","volume":"65","author":"Lessa","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C231","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1590\/S0037-86822006000400001","article-title":"An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable","volume":"39","author":"de Oliveira-Neto","year":"2006","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C232","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4269\/ajtmh.2005.73.79","article-title":"Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials","volume":"73","author":"Almeida","year":"2005","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C233","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/INF.0b013e31822dfbf7","article-title":"Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod","volume":"31","author":"Hervas","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410511424800_CIW670C234","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1128\/AAC.01023-13","article-title":"Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species","volume":"58","author":"Obonaga","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410511424800_CIW670C235","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1468-3083.2000.00004.x","article-title":"Recidivans cutaneous leishmaniasis unresponsive to liposomal amphotericin B (AmBisome)","volume":"14","author":"Gunduz","year":"2000","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2020110410511424800_CIW670C236","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1093\/jac\/dku534","article-title":"Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani","volume":"70","author":"Purkait","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C237","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1590\/S0037-86822011000200026","article-title":"American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report","volume":"44","author":"Pimentel","year":"2011","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C238","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1086\/518041","article-title":"Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis","volume":"195","author":"Arevalo","year":"2007","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C239","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1371\/journal.pmed.0030162","article-title":"Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites","volume":"3","author":"Hadighi","year":"2006","journal-title":"PLoS Med"},{"key":"2020110410511424800_CIW670C240","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.exppara.2013.01.022","article-title":"Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model","volume":"134","author":"Utaile","year":"2013","journal-title":"Exp Parasitol"},{"key":"2020110410511424800_CIW670C241","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-4362.2003.01868.x","article-title":"American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline","volume":"42","author":"Bafica","year":"2003","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C242","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1086\/324161","article-title":"Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator","volume":"33","author":"Arevalo","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C243","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/clinids\/18.5.813","article-title":"Successful treatment of cutaneous leishmaniasis with allopurinol after failure of treatment with ketoconazole","volume":"18","author":"Baum","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C244","first-page":"CD004834","article-title":"Interventions for American cutaneous and mucocutaneous leishmaniasis","author":"Gonzalez","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2020110410511424800_CIW670C245","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/521939","article-title":"Reply to Ojha et al","volume":"45","author":"Machado","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.actatropica.2007.08.003","article-title":"Mucosal leishmaniasis. Current scenario and prospects for treatment","volume":"105","author":"Amato","year":"2008","journal-title":"Acta Tropica"},{"key":"2020110410511424800_CIW670C247","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1590\/S0036-46652000000600004","article-title":"Mucosal leishmaniasis (\u201cespundia\u201d) responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil","volume":"42","author":"Oliveira-Neto","year":"2000","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"2020110410511424800_CIW670C248","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/513776","article-title":"Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis","volume":"25","author":"Llanos-Cuentas","year":"1997","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C249","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1590\/S0037-86821986000200012","article-title":"Acute airway obstruction due to oedema of the larynx following antimony therapy in mucosal leishmaniasis","volume":"19","author":"Costa","year":"1986","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C250","first-page":"131","article-title":"Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis","volume":"83","author":"Rocha","year":"1980","journal-title":"J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C251","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1111\/bjd.13355","article-title":"Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses","volume":"171","author":"Keith","year":"2014","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C252","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1503\/cmaj.131430","article-title":"Reducing the risk of infection in a 74-year-old man who is to receive prednisone","volume":"186","author":"Shafran","year":"2014","journal-title":"CMAJ"},{"key":"2020110410511424800_CIW670C253","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.trstmh.2007.05.021","article-title":"Strongyloides stercoralis septicaemia following steroid therapy for eosinophilia: report of three cases","volume":"101","author":"Ghosh","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C254","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/QCO.0b013e3283551dbd","article-title":"Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis","volume":"25","author":"Mejia","year":"2012","journal-title":"Curr Opin Infect Dis"},{"key":"2020110410511424800_CIW670C255","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4269\/ajtmh.2007.77.266","article-title":"Treatment of mucosal leishmaniasis in Latin America: systematic review","volume":"77","author":"Amato","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C256","doi-asserted-by":"crossref","first-page":"394","DOI":"10.4269\/ajtmh.1991.44.394","article-title":"Efficacy and toxicity of pentostam against Panamanian mucosal leishmaniasis","volume":"44","author":"Saenz","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C257","doi-asserted-by":"crossref","first-page":"934","DOI":"10.7326\/0003-4819-113-12-934","article-title":"Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis","volume":"113","author":"Franke","year":"1990","journal-title":"Ann Intern Med"},{"key":"2020110410511424800_CIW670C258","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4269\/ajtmh.1994.51.77","article-title":"Efficacy of 28-day and 40-day regimens of sodium stibogluconate (Pentostam) in the treatment of mucosal leishmaniasis","volume":"51","author":"Franke","year":"1994","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C259","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4269\/ajtmh.12-0729","article-title":"Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline","volume":"90","author":"Brito","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C260","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1365-4362.1971.tb01694.x","article-title":"Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases","volume":"10","author":"Sampaio","year":"1971","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C261","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1590\/S0074-02761995000400020","article-title":"A randomized trial of amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis","volume":"90","author":"Rodriguez","year":"1995","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C262","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1086\/510588","article-title":"Treatment of Bolivian mucosal leishmaniasis with miltefosine","volume":"44","author":"Soto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C263","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1093\/trstmh\/tru011","article-title":"Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients","volume":"108","author":"Rocio","year":"2014","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C264","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4269\/ajtmh.2011.11-0287","article-title":"Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?","volume":"85","author":"Amato","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C265","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1086\/510494","article-title":"Treatment of mucosal leishmaniasis with a lipid formulation of amphotericin B","volume":"44","author":"Amato","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C266","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1590\/S0037-86822008000100018","article-title":"Mucocutaneous leishmaniasis treated with liposomal amphotericin B","volume":"41","author":"Lambertucci","year":"2008","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C267","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1590\/S0037-86821997000200007","article-title":"Treatment of the mucosal form of leishmaniasis without response to glucantime, with liposomal amphotericin B [in Portuguese]","volume":"30","author":"Sampaio","year":"1997","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C268","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.4269\/ajtmh.15-0033","article-title":"Efficacy and safety of liposomal amphotericin B for the treatment of mucosal leishmaniasis from the New World: a retrospective study","volume":"93","author":"Cunha","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C269","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4269\/ajtmh.2009.81.387","article-title":"Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia","volume":"81","author":"Soto","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C270","first-page":"371","article-title":"Miltefosine versus meglumine antimoniate in the treatment of mucosal leishmaniasis [in Spanish]","volume":"74","author":"Garcia Bustos","year":"2014","journal-title":"Medicina (B Aires)"},{"key":"2020110410511424800_CIW670C271","article-title":"Briefing Document for the Anti-Infective Drugs Advisory Committee Meeting. Impavido\u00ae (miltefosine) capsules for the treatment of visceral, mucosal and cutaneous leishmaniasis"},{"key":"2020110410511424800_CIW670C272","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4269\/ajtmh.2007.76.1128","article-title":"Parenteral aminosidine is not effective for Peruvian mucocutaneous leishmaniasis","volume":"76","author":"Llanos-Cuentas","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C273","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1590\/S0037-86821998000600001","article-title":"Treatment of mucosal leishmaniasis with aminosidine sulfate: results of two year follow-up [in Portuguese]","volume":"31","author":"Romero","year":"1998","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C274","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clim.2008.05.007","article-title":"Local immunological factors associated with recurrence of mucosal leishmaniasis","volume":"128","author":"Tuon","year":"2008","journal-title":"Clin Immunol"},{"key":"2020110410511424800_CIW670C275","doi-asserted-by":"crossref","first-page":"e2657","DOI":"10.1371\/journal.pntd.0002657","article-title":"Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal","volume":"8","author":"Hasker","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C276","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1007\/s40265-013-0133-0","article-title":"Therapeutic options for visceral leishmaniasis","volume":"73","author":"Monge-Maillo","year":"2013","journal-title":"Drugs"},{"key":"2020110410511424800_CIW670C277","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.14-0743","article-title":"Amphotericin B formulations and other drugs for visceral leishmaniasis","volume":"92","author":"Berman","year":"2015","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C278","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0166-6851(86)90001-0","article-title":"Mechanism of action of amphotericin B on Leishmania donovani promastigotes","volume":"19","author":"Saha","year":"1986","journal-title":"Mol Biochem Parasitol"},{"key":"2020110410511424800_CIW670C279","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin Pharmacokinet"},{"key":"2020110410511424800_CIW670C280","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"2020110410511424800_CIW670C281","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1128\/AAC.40.5.1214","article-title":"Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome","volume":"40","author":"Gangneux","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410511424800_CIW670C282","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3109\/10611869308996089","article-title":"Activity of liposomal amphotericin B (AmBisome) against Leishmania infantum and tissue distribution in mice","volume":"1","author":"Gradoni","year":"1993","journal-title":"J Drug Target"},{"key":"2020110410511424800_CIW670C283","first-page":"75","article-title":"Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial","volume":"87","author":"Davidson","year":"1994","journal-title":"Q J Med"},{"key":"2020110410511424800_CIW670C284","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C285","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/clinids\/21.1.188","article-title":"Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions","volume":"21","author":"Seaman","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C286","first-page":"49","article-title":"Post kala-azar dermal leishmaniasis following treatment with 20 mg\/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C287","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/clinids\/22.6.938","article-title":"Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome)","volume":"22","author":"Davidson","year":"1996","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C288","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1086\/367843","article-title":"Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis","volume":"36","author":"Syriopoulou","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C289","first-page":"230","article-title":"Efficacy and tolerability of liposomal amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil","volume":"1","author":"Freire","year":"1997","journal-title":"Braz J Infect Dis"},{"key":"2020110410511424800_CIW670C290","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1371\/journal.pntd.0002613","article-title":"Safety and efficacy of single dose versus multiple doses of AmBisome(registered trademark) for treatment of visceral leishmaniasis in Eastern Africa: a randomised trial","volume":"8","author":"Khalil","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C291","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/tmi.12238","article-title":"Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?","volume":"19","author":"Salih","year":"2014","journal-title":"Trop Med Int Health"},{"key":"2020110410511424800_CIW670C292","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4269\/ajtmh.13-0150","article-title":"Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya","volume":"90","author":"Mueller","year":"2014","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C293","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1093\/clinids\/17.6.981","article-title":"Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion)","volume":"17","author":"Dietze","year":"1993","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C294","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-127-2-199707150-00007","article-title":"Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony","volume":"127","author":"Sundar","year":"1997","journal-title":"Ann Intern Med"},{"key":"2020110410511424800_CIW670C295","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/003655400459612","article-title":"Efficacy of amphotericin B colloidal dispersion in the treatment of Mediterranean visceral leishmaniasis in immunocompetent adult patients","volume":"32","author":"Gaeta","year":"2000","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C296","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0035-9203(95)90557-X","article-title":"Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days","volume":"89","author":"Dietze","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C297","first-page":"186","article-title":"Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis","volume":"47","author":"Sundar","year":"1999","journal-title":"J Assoc Physicians India"},{"key":"2020110410511424800_CIW670C298","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1080\/00034983.1998.11813337","article-title":"Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex","volume":"92","author":"Sundar","year":"1998","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C299","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1086\/500138","article-title":"Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis","volume":"42","author":"Sundar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C300","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C301","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1179\/000349804225003154","article-title":"A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis","volume":"98","author":"Thakur","year":"2004","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C302","first-page":"931","article-title":"Daily versus alternate-day regimen of amphotericin B in the treatment of kala-azar: a randomized comparison","volume":"72","author":"Thakur","year":"1994","journal-title":"Bull World Health Organ"},{"key":"2020110410511424800_CIW670C303","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1473-3099(05)70296-6","article-title":"Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980\u20132004","volume":"5","author":"Olliaro","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C304","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1016\/S0140-6736(94)90406-5","article-title":"Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar","volume":"344","author":"Mishra","year":"1994","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C305","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1086\/520665","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions","volume":"45","author":"Sundar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C306","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1056\/NEJMoa066536","article-title":"Injectable paromomycin for visceral leishmaniasis in India","volume":"356","author":"Sundar","year":"2007","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C307","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.tox.2005.07.023","article-title":"Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity","volume":"216","author":"Szebeni","year":"2005","journal-title":"Toxicology"},{"key":"2020110410511424800_CIW670C308","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1086\/374553","article-title":"Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics","volume":"36","author":"Roden","year":"2003","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C309","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/cid\/cis972","article-title":"The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B","volume":"56","author":"Farmakiotis","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C310","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1086\/519690","article-title":"Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis","volume":"196","author":"Bhattacharya","year":"2007","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C311","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/BF02763048","article-title":"Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study","volume":"73","author":"Singh","year":"2006","journal-title":"Indian J Pediatr"},{"key":"2020110410511424800_CIW670C312","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/01.inf.0000066877.72624.cb","article-title":"Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis","volume":"22","author":"Sundar","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"2020110410511424800_CIW670C313","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/cid\/civ004","article-title":"Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations","volume":"60","author":"Monge-Maillo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C314","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa021556","article-title":"Oral miltefosine for Indian visceral leishmaniasis","volume":"347","author":"Sundar","year":"2002","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C315","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1016\/S0140-6736(98)04367-0","article-title":"Trial of oral miltefosine for visceral leishmaniasis","volume":"352","author":"Sundar","year":"1998","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C316","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1086\/318121","article-title":"Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic","volume":"31","author":"Sundar","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C317","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/381203","article-title":"Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan","volume":"38","author":"Collin","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C318","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1056\/NEJM199912093412403","article-title":"Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis","volume":"341","author":"Jha","year":"1999","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C319","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1086\/505217","article-title":"A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection","volume":"43","author":"Ritmeijer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jprot.2014.05.010","article-title":"Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes","volume":"108","author":"Carnielli","year":"2014","journal-title":"J Proteomics"},{"key":"2020110410511424800_CIW670C321","doi-asserted-by":"crossref","first-page":"655","DOI":"10.4269\/ajtmh.2012.12-0022","article-title":"In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis\u2014status of newly introduced drugs","volume":"87","author":"Prajapati","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C322","doi-asserted-by":"crossref","first-page":"e1657","DOI":"10.1371\/journal.pntd.0001657","article-title":"Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis","volume":"6","author":"Bhandari","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C323","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/cid\/cit102","article-title":"Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance","volume":"56","author":"Rijal","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C324","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/cid\/cis474","article-title":"Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use","volume":"55","author":"Sundar","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C325","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0035-9203(03)90167-2","article-title":"Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline","volume":"97","author":"Rijal","year":"2003","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C326","article-title":"Sodium stibogluconate (SSG) & paromomycin combination compared to SSG for visceral leishmaniasis in East Africa: a randomised controlled trial","volume":"6:e1674","author":"Musa","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C327","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s15010-010-0022-3","article-title":"Treatment of visceral leishmaniasis in children in the central-west region of Brazil","volume":"38","author":"Brustoloni","year":"2010","journal-title":"Infection"},{"key":"2020110410511424800_CIW670C328","doi-asserted-by":"crossref","first-page":"319234","DOI":"10.1155\/2013\/319234","article-title":"Challenges in the therapy of visceral leishmaniasis in Brazil: a public health perspective","volume":"2013","author":"de Melo","year":"2013","journal-title":"J Trop Med"},{"key":"2020110410511424800_CIW670C329","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/0140-6736(92)92952-C","article-title":"Amphotericin versus pentamidine in antimony-unresponsive kala-azar","volume":"340","author":"Mishra","year":"1992","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C330","doi-asserted-by":"crossref","first-page":"435","DOI":"10.4269\/ajtmh.1991.45.435","article-title":"Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study","volume":"45","author":"Thakur","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C331","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(05)64828-3","article-title":"Treatment of kala-azar with oral fluconazole","volume":"348","author":"Sundar","year":"1996","journal-title":"Lancet"},{"key":"2020110410511424800_CIW670C332","first-page":"234","article-title":"Multiple digestive involvement in visceral leishmaniasis in a patient with HIV infection: favourable course with itraconazole [in French]","volume":"17","author":"Bechade","year":"1996","journal-title":"Rev Med Interne"},{"key":"2020110410511424800_CIW670C333","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4269\/ajtmh.1979.28.15","article-title":"Clinical and laboratory features and treatment of visceral leishmaniasis in hospitalized patients in northwestern Ethiopia","volume":"28","author":"Maru","year":"1979","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C334","first-page":"21","article-title":"Clinical, haematological and parasitological response to treatment of visceral leishmaniasis in Kenya. A study of 64 patients","volume":"36","author":"Kager","year":"1984","journal-title":"Trop Geogr Med"},{"key":"2020110410511424800_CIW670C335","first-page":"288","article-title":"The treatment of kala-azar: old and new options","volume":"44","author":"Zijlstra","year":"1992","journal-title":"Trop Geogr Med"},{"key":"2020110410511424800_CIW670C336","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.actatropica.2005.09.010","article-title":"Are there differences in clinical and laboratory parameters between children and adults with American visceral leishmaniasis?","volume":"97","author":"Caldas","year":"2006","journal-title":"Acta Tropica"},{"key":"2020110410511424800_CIW670C337","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1093\/jac\/dkh279","article-title":"A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience","volume":"54","author":"Cascio","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C338","first-page":"25","article-title":"Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries","volume":"76","author":"Berman","year":"1998","journal-title":"Bull World Health Organ"},{"key":"2020110410511424800_CIW670C339","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1056\/NEJMoa0903627","article-title":"Single-dose liposomal amphotericin B for visceral leishmaniasis in India","volume":"362","author":"Sundar","year":"2010","journal-title":"N Engl J Med"},{"key":"2020110410511424800_CIW670C340","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3476(97)70165-3","article-title":"Treatment of visceral leishmaniasis in children with liposomal amphotericin B","volume":"131","author":"di Martino","year":"1997","journal-title":"J Pediatr"},{"key":"2020110410511424800_CIW670C341","first-page":"453","article-title":"Is one year follow-up justified in kala-azar post-treatment?","volume":"71","author":"Nyakundi","year":"1994","journal-title":"East Afr Med J"},{"key":"2020110410511424800_CIW670C342","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1136\/bmj.323.7310.419","article-title":"Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial","volume":"323","author":"Sundar","year":"2001","journal-title":"BMJ"},{"key":"2020110410511424800_CIW670C343","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1086\/591972","article-title":"New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine","volume":"47","author":"Sundar","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C344","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s15010-003-3139-9","article-title":"Prognostic factors for death from visceral leishmaniasis in Teresina, Brazil","volume":"31","author":"Werneck","year":"2003","journal-title":"Infection"},{"key":"2020110410511424800_CIW670C345","doi-asserted-by":"crossref","first-page":"664","DOI":"10.7326\/0003-4819-124-7-199604010-00007","article-title":"Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources","volume":"124","author":"Seaman","year":"1996","journal-title":"Ann Intern Med"},{"key":"2020110410511424800_CIW670C346","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/j.1365-3156.2009.02305.x","article-title":"Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda","volume":"14","author":"Mueller","year":"2009","journal-title":"Trop Med Int Health"},{"key":"2020110410511424800_CIW670C347","doi-asserted-by":"crossref","first-page":"e877","DOI":"10.1371\/journal.pntd.0000877","article-title":"Risk factors for death in children with visceral leishmaniasis","volume":"4","author":"Sampaio","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C348","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1365-2133.2007.08157.x","article-title":"Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome","volume":"157","author":"Antinori","year":"2007","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C349","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1128\/JCM.43.7.3038-3041.2005","article-title":"Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure","volume":"43","author":"Maurya","year":"2005","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C350","doi-asserted-by":"crossref","first-page":"E27","DOI":"10.1542\/peds.109.2.e27","article-title":"Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children","volume":"109","author":"Cascio","year":"2002","journal-title":"Pediatrics"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C351","doi-asserted-by":"crossref","first-page":"S191","DOI":"10.1016\/S0035-9203(02)90075-1","article-title":"A nested polymerase chain reaction for diagnosis and follow-up of human visceral leishmaniasis patients using blood samples","volume":"96","author":"Fisa","year":"2002","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C352","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.actatropica.2004.08.002","article-title":"Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis","volume":"92","author":"Disch","year":"2004","journal-title":"Acta tropica"},{"key":"2020110410511424800_CIW670C353","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/infdis\/171.3.751","article-title":"Diagnosis of symptomatic visceral leishmaniasis by use of the polymerase chain reaction on patient blood","volume":"171","author":"Nuzum","year":"1995","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C354","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1086\/515289","article-title":"A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy","volume":"177","author":"Houghton","year":"1998","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C355","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4269\/ajtmh.2000.63.153","article-title":"Use of the recombinant K39 dipstick test and the direct agglutination test in a setting endemic for visceral leishmaniasis in Nepal","volume":"63","author":"Bern","year":"2000","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C356","doi-asserted-by":"crossref","first-page":"739","DOI":"10.4269\/ajtmh.2006.75.739","article-title":"Immunologic tests in patients after clinical cure of visceral leishmaniasis","volume":"75","author":"De Almeida Silva","year":"2006","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C357","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1473-3099(03)00517-6","article-title":"Post-kala-azar dermal leishmaniasis","volume":"3","author":"Zijlstra","year":"2003","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C358","doi-asserted-by":"crossref","first-page":"e1872","DOI":"10.1371\/journal.pntd.0001872","article-title":"Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey","volume":"6","author":"Mueller","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C359","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1186\/s12889-015-2424-8","article-title":"Clinico-epidemiological analysis of post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study","volume":"15","author":"Ramesh","year":"2015","journal-title":"BMC Public Health"},{"key":"2020110410511424800_CIW670C360","doi-asserted-by":"crossref","first-page":"e0004138","DOI":"10.1371\/journal.pntd.0004138","article-title":"PKDL\u2014a silent parasite pool for transmission of leishmaniasis in kala-azar endemic areas of Malda District, West Bengal, India","volume":"9","author":"Ganguly","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C361","article-title":"The post kala-azar dermal leishmaniasis (PKDL) atlas: a manual for health workers","author":"World Health Organization"},{"key":"2020110410511424800_CIW670C362","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.2012.11-0682","article-title":"Leishmaniasis in the United States: treatment in 2012","volume":"86","author":"Murray","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C363","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1086\/595710","article-title":"Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum","volume":"48","author":"Lachaud","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C364","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1590\/S0074-02762010000500016","article-title":"HIV\/AIDS-associated visceral leishmaniasis in patients from an endemic area in central-west Brazil","volume":"105","author":"Alexandrino-de-Oliveira","year":"2010","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C365","doi-asserted-by":"crossref","first-page":"e152","DOI":"10.1093\/cid\/cir674","article-title":"Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence","volume":"53","author":"Ritmeijer","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C366","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1093\/cid\/cir521","article-title":"Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India","volume":"53","author":"Sinha","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C367","first-page":"46","article-title":"Five-year field results and long-term effectiveness of 20 mg\/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C368","doi-asserted-by":"crossref","first-page":"e3053","DOI":"10.1371\/journal.pntd.0003053","article-title":"Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)","volume":"8","author":"Burza","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C369","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/clinids\/21.3.711","article-title":"Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus","volume":"21","author":"Laguna","year":"1995","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0163-4453(96)91343-2","article-title":"Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome)","volume":"32","author":"Russo","year":"1996","journal-title":"J Infect"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C371","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1179\/000349803225002606","article-title":"Treatment of leishmaniasis in HIV-positive patients","volume":"97","author":"Laguna","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C372","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1086\/507530","article-title":"Liposomal amphotericin B for the treatment of visceral leishmaniasis","volume":"43","author":"Bern","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C373","doi-asserted-by":"crossref","first-page":"e2195","DOI":"10.1371\/journal.pntd.0002195","article-title":"Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison","volume":"7","author":"Cota","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C374","doi-asserted-by":"crossref","first-page":"766","DOI":"10.4269\/ajtmh.1999.61.766","article-title":"High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients","volume":"61","author":"Delgado","year":"1999","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C375","doi-asserted-by":"crossref","first-page":"e2875","DOI":"10.1371\/journal.pntd.0002875","article-title":"High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia","volume":"8","author":"Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C376","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/00002030-199906180-00009","article-title":"Treatment of visceral leishmaniasis in HIV-infected patients: a randomized trial comparing meglumine antimoniate with amphotericin B. Spanish HIV-Leishmania Study Group","volume":"13","author":"Laguna","year":"1999","journal-title":"AIDS"},{"key":"2020110410511424800_CIW670C377","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jac\/dkg356","article-title":"Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study","volume":"52","author":"Laguna","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C378","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1086\/425359","article-title":"Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection","volume":"39","author":"Sindermann","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C379","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/00365540701466215","article-title":"Long term failure of miltefosine in the treatment of refractory visceral leishmaniasis in AIDS patients","volume":"40","author":"Troya","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C380","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/00365540701787800","article-title":"Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients","volume":"40","author":"Marques","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C381","doi-asserted-by":"crossref","first-page":"e2869","DOI":"10.1371\/journal.pntd.0002869","article-title":"Visceral leishmaniasis and HIV coinfection in East Africa","volume":"8","author":"Diro","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C382","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/civ530","article-title":"Combination treatment for visceral leishmaniasis patients coinfected with human immunodeficiency virus in India","volume":"61","author":"Mahajan","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C383","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1179\/000349803225002615","article-title":"The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV","volume":"97","author":"Lopez-Velez","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C384","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1179\/000349803225002570","article-title":"Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections","volume":"97","author":"Russo","year":"2003","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C385","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1086\/344325","article-title":"Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus","volume":"186","author":"del Giudice","year":"2002","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C386","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1086\/318708","article-title":"Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients","volume":"32","author":"de la Rosa","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C387","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1128\/JCM.40.3.762-767.2002","article-title":"Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy","volume":"40","author":"de La Rosa","year":"2002","journal-title":"J Clin Microbiol"},{"key":"2020110410511424800_CIW670C388","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00126334-200207010-00015","article-title":"Highly active antiretroviral therapy (HAART) modifies the incidence and outcome of visceral leishmaniasis in HIV-infected patients","volume":"30","author":"Tortajada","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2020110410511424800_CIW670C389","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1473-3099(12)70348-1","article-title":"HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals","volume":"13","author":"van Griensven","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"2020110410511424800_CIW670C390","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1086\/591459","article-title":"Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries","volume":"198","author":"Dooley","year":"2008","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C391","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1097\/QCO.0b013e3282a6463d","article-title":"Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy","volume":"20","author":"Lawn","year":"2007","journal-title":"Curr Opin Infect Dis"},{"key":"2020110410511424800_CIW670C392","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/2325957414555225","article-title":"Leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients: a literature review","volume":"14","author":"Badaro","year":"2015","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"2020110410511424800_CIW670C393","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1097\/00002030-199816000-00019","article-title":"Leishmaniosis\u2014new perspectives on an underappreciated opportunistic infection","volume":"12","author":"Albrecht","year":"1998","journal-title":"AIDS"},{"key":"2020110410511424800_CIW670C394","first-page":"152","article-title":"Visceral leishmaniasis in HIV-infected patients with non-detectable HIV-1 viral load after highly active antiretroviral therapy","volume":"13","author":"Jimenez-Exposito","year":"1999","journal-title":"AIDS"},{"key":"2020110410511424800_CIW670C395","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/00365540410019426","article-title":"Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant with immune reconstitution due to antiretroviral therapy","volume":"36","author":"Berry","year":"2004","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C396","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1179\/136485906X91440","article-title":"Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy","volume":"100","author":"Belay","year":"2006","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C397","first-page":"77","article-title":"Leishmaniasis (PKDL) as a case of immune reconstitution inflammatory syndrome (IRIS) in HIV-positive patient after initiation of anti-retroviral therapy (ART)","volume":"47","author":"Tadesse","year":"2009","journal-title":"Ethiop Med J"},{"key":"2020110410511424800_CIW670C398","first-page":"451","article-title":"Post-kala-azar dermal leishmaniasis manifesting after initiation of highly active anti-retroviral therapy in a patient with human immunodeficiency virus infection","volume":"3","author":"Gilad","year":"2001","journal-title":"Isr Med Assoc J"},{"key":"2020110410511424800_CIW670C399","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1468-1293.2010.00846.x","article-title":"\u2018Active chronic visceral leishmaniasis\u2019 in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients","volume":"11","author":"Bourgeois","year":"2010","journal-title":"HIV Med"},{"key":"2020110410511424800_CIW670C400","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/jac\/dkh084","article-title":"Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"53","author":"Lopez-Velez","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C401","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1093\/jac\/dkm294","article-title":"Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients","volume":"60","author":"Molina","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C402","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00002030-199602000-00023","article-title":"Pentamidine isethionate as secondary prophylaxis against visceral leishmaniasis in HIV-positive patients","volume":"10","author":"Perez-Molina","year":"1996","journal-title":"AIDS"},{"key":"2020110410511424800_CIW670C403","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1111\/j.1365-3156.2009.02329.x","article-title":"Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases","volume":"14","author":"Patel","year":"2009","journal-title":"Trop Med Int Health"},{"key":"2020110410511424800_CIW670C404","doi-asserted-by":"crossref","first-page":"e0004087","DOI":"10.1371\/journal.pntd.0004087","article-title":"Use of pentamidine as secondary prophylaxis to prevent visceral leishmaniasis relapse in HIV infected patients: the first twelve months of a prospective cohort study","volume":"9","author":"Diro","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C405","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0002-9343(97)89503-4","article-title":"Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients","volume":"100","author":"Ribera","year":"1996","journal-title":"Am J Med"},{"key":"2020110410511424800_CIW670C406","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3201\/eid1804.110841","article-title":"Leishmania resistance to miltefosine associated with genetic marker","volume":"18","author":"Cojean","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"2020110410511424800_CIW670C407","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1097\/00002030-200012220-00020","article-title":"Discontinuation of secondary anti-leishmania prophylaxis in HIV-infected patients who have responded to highly active antiretroviral therapy","volume":"14","author":"Berenguer","year":"2000","journal-title":"AIDS"},{"key":"2020110410511424800_CIW670C408","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1086\/587899","article-title":"Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome","volume":"46","author":"ter Horst","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C409","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1007\/s100960000364","article-title":"Prospective evaluation and follow-up of European patients with visceral leishmaniasis and HIV-1 coinfection in the era of highly active antiretroviral therapy","volume":"19","author":"Villanueva","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410511424800_CIW670C410","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jinf.2011.03.012","article-title":"Mucosal Leishmania infantum leishmaniasis: specific pattern in a multicentre survey and historical cases","volume":"63","author":"Faucher","year":"2011","journal-title":"J Infect"},{"key":"2020110410511424800_CIW670C411","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.md.0000076009.64510.b8","article-title":"Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients","volume":"82","author":"Aliaga","year":"2003","journal-title":"Medicine (Baltimore)"},{"key":"2020110410511424800_CIW670C412","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s100960000328","article-title":"Oral leishmaniasis in an HIV-infected patient","volume":"19","author":"Cascio","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020110410511424800_CIW670C413","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.parint.2013.10.002","article-title":"Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy","volume":"63","author":"Madeddu","year":"2014","journal-title":"Parasitol Int"},{"key":"2020110410511424800_CIW670C414","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000246860","article-title":"Mucocutaneous leishmaniasis and HIV","volume":"189","author":"Miralles","year":"1994","journal-title":"Dermatology"},{"key":"2020110410511424800_CIW670C415","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1590\/S0074-02761992000400005","article-title":"Disseminated American muco-cutaneous leishmaniasis caused by Leishmania braziliensis braziliensis in a patient with AIDS: a case report","volume":"87","author":"Machado","year":"1992","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"2020110410511424800_CIW670C416","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1590\/S0037-86822002000600017","article-title":"American cutaneous leishmaniasis associated with HIV\/AIDS: report of four clinical cases [in Portuguese]","volume":"35","author":"Sampaio","year":"2002","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C417","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jac\/46.2.341","article-title":"Mucocutaneous leishmaniasis associated with HIV infection treated successfully with liposomal amphotericin B (AmBisome)","volume":"46","author":"Amato","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C418","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.actatropica.2004.06.006","article-title":"Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients","volume":"92","author":"Amato","year":"2004","journal-title":"Acta Tropica"},{"key":"2020110410511424800_CIW670C419","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7705\/biomedica.v26i4.314","article-title":"Diffuse cutaneous leishmaniasis in a patient with AIDS [in Spanish]","volume":"26","author":"P\u00e9rez","year":"2006","journal-title":"Biomedica"},{"key":"2020110410511424800_CIW670C420","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1086\/430444","article-title":"Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1","volume":"40","author":"Schraner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C421","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1086\/497338","article-title":"Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS","volume":"192","author":"Posada-Vergara","year":"2005","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C422","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4269\/ajtmh.2009.09-0077","article-title":"Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis","volume":"81","author":"Chrusciak-Talhari","year":"2009","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C423","first-page":"187","article-title":"Dermatologic manifestations associated with immune reconstitution syndrome in HIV+ patients starting HAART: a retrospective study in French Guiana [in French]","volume":"98","author":"Sarazin","year":"2005","journal-title":"Bull Soc Pathol Exot"},{"key":"2020110410511424800_CIW670C424","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/j.1365-4632.2008.03804.x","article-title":"Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome","volume":"47","author":"Sinha","year":"2008","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C425","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1086\/506572","article-title":"First case of cutaneous reconstitution inflammatory syndrome associated with HIV infection and leishmaniasis","volume":"43","author":"Kerob","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C426","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1086\/338720","article-title":"Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS","volume":"34","author":"Blanche","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C427","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12879-015-0774-6","article-title":"Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report","volume":"15","author":"Gois","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2020110410511424800_CIW670C428","doi-asserted-by":"crossref","first-page":"e1032","DOI":"10.1016\/j.ijid.2010.06.019","article-title":"Leishmaniasis, an emerging infection in travelers","volume":"14","author":"Pavli","year":"2010","journal-title":"Int J Infect Dis"},{"key":"2020110410511424800_CIW670C429","doi-asserted-by":"crossref","DOI":"10.2807\/ese.17.26.20205-en","article-title":"Infectious diseases among travellers and migrants in Europe, EuroTravNet 2010","volume":"17","author":"Gautret","year":"2012","journal-title":"Euro Surveill"},{"key":"2020110410511424800_CIW670C430","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1093\/cid\/cir468","article-title":"Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience","volume":"53","author":"Flores-Figueroa","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C431","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1708-8305.2009.00341.x","article-title":"Imported leishmaniasis: a heterogeneous group of diseases","volume":"16","author":"Perez-Ayala","year":"2009","journal-title":"J Travel Med"},{"key":"2020110410511424800_CIW670C432","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/00365540903104127","article-title":"Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis","volume":"41","author":"Buonomano","year":"2009","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C433","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1128\/CMR.00021-07","article-title":"Transmission of tropical and geographically restricted infections during solid-organ transplantation","volume":"21","author":"Martin-Davila","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"2020110410511424800_CIW670C434","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.idc.2013.02.008","article-title":"Parasitic infections in solid organ transplant recipients","volume":"27","author":"Coster","year":"2013","journal-title":"Infect Dis Clin North Am"},{"key":"2020110410511424800_CIW670C435","doi-asserted-by":"crossref","first-page":"20546","DOI":"10.2807\/1560-7917.ES2013.18.30.20546","article-title":"Re-emergence of leishmaniasis in Spain: community outbreak in Madrid, Spain, 2009 to 2012","volume":"18","author":"Arce","year":"2013","journal-title":"Euro Surveill"},{"key":"2020110410511424800_CIW670C436","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.healun.2007.09.005","article-title":"Visceral leishmaniasis in an Italian heart recipient: first case report","volume":"26","author":"Larocca","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"2020110410511424800_CIW670C437","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/S1053-2498(01)00263-7","article-title":"Fatal visceral leishmaniasis in a heart transplant recipient","volume":"20","author":"Frapier","year":"2001","journal-title":"J Heart Lung Transplant"},{"issue":"4 pt 1","key":"2020110410511424800_CIW670C438","first-page":"820","article-title":"Leishmaniasis in a heart transplant patient","volume":"11","author":"Golino","year":"1992","journal-title":"J Heart Lung Transplant"},{"key":"2020110410511424800_CIW670C439","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0041-1345(03)00664-X","article-title":"Visceral leishmaniasis in lung transplantation","volume":"35","author":"Morales","year":"2003","journal-title":"Transplant Proc"},{"key":"2020110410511424800_CIW670C440","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cmi.2014.09.002","article-title":"Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study","volume":"21","author":"Clemente","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2020110410511424800_CIW670C441","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/1471-2334-6-177","article-title":"Leishmania infantum leishmaniasis in corticosteroid-treated patients","volume":"6","author":"Pittalis","year":"2006","journal-title":"BMC Infect Dis"},{"key":"2020110410511424800_CIW670C442","doi-asserted-by":"crossref","first-page":"e0121418","DOI":"10.1371\/journal.pone.0121418","article-title":"Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, London","volume":"10","author":"Fletcher","year":"2015","journal-title":"PLoS One"},{"key":"2020110410511424800_CIW670C443","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/0002-9343(87)90948-X","article-title":"Visceral leishmaniasis in immunocompromised hosts","volume":"83","author":"Fernandez-Guerrero","year":"1987","journal-title":"Am J Med"},{"key":"2020110410511424800_CIW670C444","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1469-0691.2011.03674.x","article-title":"Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe","volume":"18","author":"Zanger","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2020110410511424800_CIW670C445","doi-asserted-by":"crossref","first-page":"e0003594","DOI":"10.1371\/journal.pntd.0003594","article-title":"Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997\u20132011: raising awareness towards leishmaniasis in non-HIV patients","volume":"9","author":"Herrador","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C446","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ad.2014.12.003","article-title":"Cutaneous leishmaniasis: 20 years\u2019 experience in a Spanish tertiary care hospital","volume":"106","author":"Giavedoni","year":"2015","journal-title":"Actas Dermosifiliogr"},{"key":"2020110410511424800_CIW670C447","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.trstmh.2007.08.003","article-title":"Aspects of the association between leishmaniasis and malignant disorders","volume":"101","author":"Kopterides","year":"2007","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C448","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.actatropica.2003.09.009","article-title":"Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis","volume":"90","author":"Fernandez-Guerrero","year":"2004","journal-title":"Acta Trop"},{"issue":"suppl 4","key":"2020110410511424800_CIW670C449","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/ajt.12120","article-title":"Parasitic infections in solid organ transplantation","volume":"13","author":"Schwartz","year":"2013","journal-title":"Am J Transplant"},{"key":"2020110410511424800_CIW670C450"},{"key":"2020110410511424800_CIW670C451","doi-asserted-by":"crossref","first-page":"e0004304","DOI":"10.1371\/journal.pntd.0004304","article-title":"Antimony to cure visceral leishmaniasis unresponsive to liposomal amphotericin B","volume":"10","author":"Morizot","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C452","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.tmaid.2013.05.003","article-title":"Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-(alpha) antagonists","volume":"11","author":"Neumayr","year":"2013","journal-title":"Travel Med Infect Dis"},{"key":"2020110410511424800_CIW670C453","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1399-3062.2010.00520.x","article-title":"Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management","volume":"12","author":"Veroux","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"2020110410511424800_CIW670C454","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1399-3062.2011.00598.x","article-title":"Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature","volume":"13","author":"Simon","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"2020110410511424800_CIW670C455","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ajt.12521","article-title":"High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil","volume":"14","author":"Clemente","year":"2014","journal-title":"Am J Transplant"},{"key":"2020110410511424800_CIW670C456","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1590\/0037-8682-0104-2013","article-title":"Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence","volume":"46","author":"Silva","year":"2013","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C457","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/1064744042000210384","article-title":"Visceral leishmaniasis (kala-azar) and pregnancy","volume":"12","author":"Figueiro-Filho","year":"2004","journal-title":"Infect Dis Obstet Gynecol"},{"key":"2020110410511424800_CIW670C458","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00404-007-0532-0","article-title":"Visceral leishmaniasis and pregnancy: analysis of cases reported in a central-western region of Brazil","volume":"278","author":"Figueiro-Filho","year":"2008","journal-title":"Arch Gynecol Obstet"},{"key":"2020110410511424800_CIW670C459","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/jac\/dkl342","article-title":"A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan","volume":"58","author":"Mueller","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C460","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ijgo.2009.08.002","article-title":"Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan","volume":"107","author":"Adam","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"2020110410511424800_CIW670C461","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/jac\/dkh538","article-title":"Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature","volume":"55","author":"Pagliano","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C462","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00365549409011824","article-title":"Mediterranean visceral leishmaniasis in pregnancy","volume":"26","author":"Gradoni","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"2020110410511424800_CIW670C463","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0001-706X(03)00160-8","article-title":"Visceral leishmaniasis in pregnancy: a case report","volume":"88","author":"Caldas","year":"2003","journal-title":"Acta Tropica"},{"key":"2020110410511424800_CIW670C464","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1179\/136485908X278766","article-title":"Visceral leishmaniasis in pregnancy\u2014the role of amphotericin B","volume":"102","author":"Topno","year":"2008","journal-title":"Ann Trop Med Parasitol"},{"key":"2020110410511424800_CIW670C465","first-page":"263","article-title":"The treatment of kala-azar during pregnancy","volume":"6","author":"Thakur","year":"1993","journal-title":"Natl Med J India"},{"key":"2020110410511424800_CIW670C466","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0890-6238(01)00127-7","article-title":"Embryotoxicity of meglumine antimoniate in the rat","volume":"15","author":"Paumgartten","year":"2001","journal-title":"Reprod Toxicol"},{"key":"2020110410511424800_CIW670C467","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00204-009-0485-0","article-title":"Genotoxic effects of the antileishmanial drug Glucantime","volume":"84","author":"Lima","year":"2010","journal-title":"Arch Toxicol"},{"issue":"suppl 1","key":"2020110410511424800_CIW670C468","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.trstmh.2006.02.010","article-title":"Development of miltefosine as an oral treatment for leishmaniasis","volume":"100","author":"Sindermann","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C469","article-title":"Miltefosine. Highlights of prescribing information","author":"Food and Drug Administration"},{"key":"2020110410511424800_CIW670C470","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1093\/jac\/dks164","article-title":"Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine","volume":"67","author":"Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C471","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020110410511424800_CIW670C472","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1086\/648726","article-title":"Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan","volume":"50","author":"van Thiel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C473","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1610-0387.2007.06377.x","article-title":"Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature","volume":"5","author":"Valesky","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"2020110410511424800_CIW670C474","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1086\/520017","article-title":"Cutaneous leishmaniasis during pregnancy: exuberant lesions and potential fetal complications","volume":"45","author":"Morgan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C475","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.trstmh.2009.04.019","article-title":"Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil","volume":"103","author":"Guimaraes","year":"2009","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C476","article-title":"Two women presenting worsening cutaneous ulcers during pregnancy: diagnosis, immune response, and follow-up","volume":"7:e2472","author":"Conceicao-Silva","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C477","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1517\/14740338.4.4.745","article-title":"Drug use and breastfeeding","volume":"4","author":"Ilett","year":"2005","journal-title":"Expert Opin Drug Saf"},{"key":"2020110410511424800_CIW670C478","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/0035-9203(89)90327-1","article-title":"Concentration of Pentostam in human breast milk","volume":"83","author":"Berman","year":"1989","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C479","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jaad.2013.12.047","article-title":"Leishmania tropica in children: a retrospective study","volume":"71","author":"Solomon","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2020110410511424800_CIW670C480","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/bjd.13496","article-title":"Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A critically appraised topic","volume":"172","author":"Burden-Teh","year":"2015","journal-title":"Br J Dermatol"},{"key":"2020110410511424800_CIW670C481","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1111\/j.1365-4632.2012.05460.x","article-title":"Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis","volume":"51","author":"Esfandiarpour","year":"2012","journal-title":"Int J Dermatol"},{"key":"2020110410511424800_CIW670C482","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/tropej\/fmp132","article-title":"Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial","volume":"56","author":"Singh","year":"2010","journal-title":"J Trop Pediatr"},{"key":"2020110410511424800_CIW670C483","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.arcped.2005.01.009","article-title":"First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France [in French]","volume":"12","author":"Minodier","year":"2005","journal-title":"Arch Pediatr"},{"key":"2020110410511424800_CIW670C484","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4269\/ajtmh.2001.64.187","article-title":"Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania Viannia species","volume":"64","author":"Palacios","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C485","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/infdis\/jir816","article-title":"Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children","volume":"205","author":"Rubiano","year":"2012","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C486","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4269\/ajtmh.2011.10-0002","article-title":"Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults","volume":"84","author":"Layegh","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C487","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1086\/510860","article-title":"Pharmacokinetics of antimony in children treated for leishmaniasis with meglumine antimoniate","volume":"195","author":"Cruz","year":"2007","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C488","article-title":"Miltefosine (Impavido\u00ae) for the treatment of visceral, mucosal and cutaneous leishmaniasis","author":"Food and Drug Administration"},{"key":"2020110410511424800_CIW670C489","doi-asserted-by":"crossref","first-page":"e912","DOI":"10.1371\/journal.pntd.0000912","article-title":"Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial","volume":"4","author":"Machado","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C490","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4269\/ajtmh.2011.10-0155","article-title":"Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil","volume":"84","author":"Chrusciak-Talhari","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C491","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1086\/380638","article-title":"Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India","volume":"38","author":"Bhattacharya","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2020110410511424800_CIW670C492","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4269\/ajtmh.2011.10-0661","article-title":"Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh","volume":"85","author":"Rahman","year":"2011","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C493","doi-asserted-by":"crossref","first-page":"e100220","DOI":"10.1371\/journal.pone.0100220","article-title":"Failure of miltefosine treatment for visceral leishmaniasis in children and men in south-east Asia","volume":"9","author":"Ostyn","year":"2014","journal-title":"PLoS One"},{"key":"2020110410511424800_CIW670C494","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1128\/AAC.00292-12","article-title":"Optimal dosing of miltefosine in children and adults with visceral leishmaniasis","volume":"56","author":"Dorlo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410511424800_CIW670C495","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/infdis\/jiu039","article-title":"Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure","volume":"210","author":"Dorlo","year":"2014","journal-title":"J Infect Dis"},{"key":"2020110410511424800_CIW670C496","doi-asserted-by":"crossref","first-page":"257","DOI":"10.4269\/ajtmh.2012.11-0612","article-title":"Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006)","volume":"87","author":"Vasconcellos","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C497","doi-asserted-by":"crossref","first-page":"296","DOI":"10.4269\/ajtmh.1992.46.296","article-title":"Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies","volume":"46","author":"Herwaldt","year":"1992","journal-title":"Am J Trop Med Hyg"},{"key":"2020110410511424800_CIW670C498","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1128\/AAC.01298-10","article-title":"High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B","volume":"55","author":"Chappuis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2020110410511424800_CIW670C499","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1590\/S0037-86822012000500011","article-title":"The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil","volume":"45","author":"Diniz","year":"2012","journal-title":"Rev Soc Bras Med Trop"},{"key":"2020110410511424800_CIW670C500","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.actatropica.2011.02.007","article-title":"Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World","volume":"118","author":"Oliveira","year":"2011","journal-title":"Acta Tropica"},{"key":"2020110410511424800_CIW670C501","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.trstmh.2005.03.012","article-title":"Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers","volume":"100","author":"Lawn","year":"2006","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020110410511424800_CIW670C502","doi-asserted-by":"crossref","first-page":"e1688","DOI":"10.1371\/journal.pntd.0001688","article-title":"Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]","volume":"6","author":"Wise","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"2020110410511424800_CIW670C503","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4269\/ajtmh.1985.34.702","article-title":"Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate)","volume":"34","author":"Chulay","year":"1985","journal-title":"Am J Trop Med Hyg"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/12\/e202\/34129726\/ciw670.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/63\/12\/e202\/34129726\/ciw670.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T22:30:46Z","timestamp":1749594646000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/63\/12\/e202\/2645609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,7]]},"references-count":503,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,7]]},"published-print":{"date-parts":[[2016,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciw670","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,12,15]]},"published":{"date-parts":[[2016,12,7]]}}}